論文・技術情報追加のお知らせ

1. A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database.

タクロリムスはシクロスポリンより腎障害の発症が強い

対象DB：FAERS

2. Biomaterial-based drug delivery: evaluating the safety profiles of liposomal Vyxeos.

ビキセオスは血液学的、感染症、心疾患に関連する有害事象が多く報告

対象DB：FAERS

3. Post-marketing Safety Evaluation of Lutathera (177Lu-DOTATATE): A Pharmacovigilance Analysis of FDA Adverse Event Reporting System.

ルタテラの使用で内分泌障害や重篤な有害事象が確認

対象DB：FAERS

4. Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology.

薬剤性膵炎のリスクがある101薬剤を特定

対象DB：FAERS

5. A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database.

エフガルチモドアルファは感染症や腎結石に関するリスクが示唆された

対象DB：FAERS

6. FAERS based disproportionality analysis and network pharmacology investigation of taxanes associated drug induced liver injury.

パクリタキセルとナブ-パクリタキセルは肝障害リスクが高い

対象DB：FAERS

7. Disproportionality Analysis of ALK Inhibitor-Induced Hemolytic Adverse Events: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.

アレクチニブは溶血のリスクが高い

対象DB：FAERS

8. Neurological adverse events associated with baclofen: A disproportionality analysis based on FDA Adverse Event Reporting System.

バクロフェンの神経系副作用には注意が必要

対象DB：FAERS

9. Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system.

多発性骨髄腫治療薬で肺関連副作用が確認

対象DB：FAERS

10. Risk of thromboembolic events in patients co-treated with factor Xa-inhibiting direct oral anticoagulants and anti-seizure medications: insights from pharmacovigilance data.

FXa-DOACsと抗けいれん薬併用で血栓症リスク増加

対象DB：FAERS

11. Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system.

レンバチニブの単独療法と併用療法での消化器系副作用を比較分析

対象DB：FAERS

12. Evaluating adverse events of pegvaliase-pqpz in phenylketonuria treatment: A comprehensive safety assessment.

ペグバリアーゼの副作用とリスク要因を分析

対象DB：FAERS

13. Establishment of a visualization platform for ADR query and analysis: an example of severe skin adverse reactions caused by sulfonylureas.

薬物安全性監視を効率化するツールの開発

対象DB：FAERS

14. Adverse Reactions With VEGF Inhibitors in Combination With NSAIDs: Disproportionality Analysis Using JADRE and FAERS.

VEGF阻害薬とNSAIDの併用は消化管穿孔リスクを増加

対象DB：FAERS,JADER

15. A Real-world Pharmacovigilance Study Of FDA Adverse Event Reporting System (FAERS) Events For Gender Of Voriconazole Drugs.

ボリコナゾール副作用に性差が見られた

対象DB：FAERS

16. Comparative Analysis of Adverse Event Profiles Among Seven Statins for Hypercholesterolemia Management Using the United States FDA Adverse Event Reporting System.

スタチン間で副作用発現パターンに差

対象DB：FAERS

17. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Avelumab.

アベルマブは甲状腺・腎障害等に注意必要

対象DB：FAERS

18. Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System.

免疫チェックポイント阻害薬で心房細動の報告頻度増加

対象DB：FAERS

19. Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting system.

ソトラシブとアダグラシブに新たな副作用の兆候

対象DB：FAERS

20. Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.

皮下注と経口セマグルチドで眼障害頻度に差

対象DB：FAERS

21. Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study: Ocular Adverse Events of Pegcetacoplan & Avacincaptad Pegol.

ペグセタコプランに多様な眼有害事象を検出

対象DB：FAERS

22. Post-Marketing Safety Analysis of Upadacitinib in Atopic Dermatitis: An FDA Adverse Reporting System (FAERS) Review of Boxed Warning Related Adverse Events.

ウパダシチニブで警告関連有害事象を検出

対象DB：FAERS

23. Association of antibiotics with Stevens-Johnson syndrome and toxic epidermal necrolysis: a real-world pharmacovigilance study.

特定抗菌薬でSJS/TENリスク上昇確認

対象DB：FAERS

24. Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: analysis of The FDA Adverse Event Reporting System (FAERS).

SSRIと他薬併用でセロトニン症候群リスク増

対象DB：FAERS

25. Tacrolimus-Related Fanconi Syndrome: A Real World Pharmacovigilance Study based on FDA Adverse Event Reporting System (FAERS) Database.

タクロリムスは60歳以上でファンコニ症候群のリスクが増加

対象DB：FAERS

26. A Real-World Pharmacovigilance Analysis of Lorlatinib-Associated Metabolic Effects Using The FDA Adverse Events Reporting System (FAERS) Database From 2013 to 2024.

ロルラチニブは、高コレステロールや体重増加などの代謝副作用が関連

対象DB：FAERS

27. Post-marketing safety of pralsetinib: a real-world disproportionality analysis based on the FDA adverse event reporting system database.

プラルセチニブは高血圧や貧血などの副作用が報告された

対象DB：FAERS

28. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.

混合型GLP-1受容体作動薬は、副作用や品質問題が多い

対象DB：FAERS

29. Nephrotoxicity risks of colistin-combination therapy: a USFDA adverse event reporting system analysis using disproportionality and interaction assessment.

コリスチンと他薬の併用は腎毒性リスク増大

対象DB：FAERS

30. Expanded Spectrum and Increased Incidence of Adverse Events Linked to COVID-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges.

mRNAワクチンは重篤な副作用が多く報告

対象DB：FAERS,KAERS,VAERS

31. Mechanistic Insights into Drug-Induced Guillain-Barre Syndrome: A Large-Cohort Analysis of the FAERS Database.

薬剤誘発型GBSの生物学的メカニズムを解明し、治療ターゲットを特定

対象DB：FAERS

32. The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database.

併用療法は特定の副作用リスクを高め、個別化治療が重要

対象DB：FAERS

33. Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS.

リフィテグラストの副作用には眼の炎症や緑内障があり、65歳以上で多い

対象DB：FAERS

34. Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system.

ルカネマブの副作用として、特に睡眠障害が注目されている

対象DB：FAERS

35. The safety analysis of lurasidone based on the real-world data of FAERS database.

ルラシドンの新たな副作用に眼や授乳関連が含まれる

対象DB：FAERS

36. Pancreatitis associated with BRAF inhibitors: a disproportionality analysis based on the Food and Drug Administration Adverse Event Reporting System.

BRAF阻害薬は膵炎のリスクを高め、特に治療初期に発症しやすい

対象DB：FAERS

37. Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database.

ペムブロリズマブの副作用は、血液学的障害や内分泌機能障害が多い

対象DB：FAERS

38. Risk of medication-induced lactic acidosis and hyperlactatemia: a pharmacovigilance study of the United States Food and Drug Administration's Adverse Event Reporting System database.

メトホルミンやラインゾリドがLAHLリスク

対象DB：FAERS

39. Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004-2024).

ガニレリクスに流産などの予期せぬシグナル

対象DB：FAERS,JADER

40. Post-market safety profile and suicide/self-injury risk signals of dextromethorphan/bupropion: a real-world pharmacovigilance study.

D/Bは精神・神経系有害事象に注意要

対象DB：FAERS

41. A Drug Similarity-Based Bayesian Method for Early Adverse Drug Event Detection.

類似薬情報で副作用検出を迅速化

対象DB：FAERS

42. Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system.

CGRP阻害薬で脱毛・便秘等の新副作用

対象DB：FAERS,KAERS

43. A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS).

ネタルスジルで新たな眼・全身副作用を確認

対象DB：FAERS

44. Immune Checkpoint Inhibitor-induced Uveitis: Disproportionality and Timing Analyses of the Japanese Pharmacovigilance Database.

免疫チェックポイント阻害薬でぶどう膜炎発症、特に女性に早期

対象DB：JADER

45. HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database.

HIF-PHIで血栓リスク増、特に女性と非透析群

対象DB：JADER

46. H1 antihistamine-induced adverse events and time to onset: A retrospective analysis using the Japanese Adverse Drug Event Report Database.

H1抗ヒスタミン薬で重篤な副作用が発生

対象DB：JADER

47. Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination.

mRNAワクチンは免疫疾患報告が多い傾向

対象DB：EudraVigilance

48. Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance.

ニラパリブは重篤な副作用が多く注意

対象DB：EudraVigilance

49. Bevacizumab-Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment.

ベバシズマブは血管障害が多く、高齢者に注意

対象DB：EudraVigilance

50. Oral Adverse Effects of Antipsychotic Medications: A Case/Noncase Analysis of EudraVigilance Data.

抗精神病薬は口腔健康に影響、予防歯科ケアが重要

対象DB：EudraVigilance

51. Identification of Anticancer Drugs Associated to Cancer Therapy-Related Cardiac Dysfunction: A VigiBase(R) Disproportionality Analysis.

25の抗がん剤がCTRCD報告と関連。新たなシグナルも確認

対象DB：VigiBase

52. Identification of Anticancer Drugs Associated With Cancer Therapy-Related Cardiac Dysfunction in Pediatrics-Analysis of the WHO Pharmacovigilance Database.

16の抗がん剤が小児のCTRCDと関連

対象DB：VigiBase

53. Current status and trends in ERCP and post-ERCP pancreatitis in Japan: a nationwide observational study.

ERCPの件数増加に伴い、PEP発生率は減少。NSAIDsが重症PEP予防に有効

対象DB：DPC

54. Association of comorbid schizophrenia with cancer stage at admission, treatments, length of stay, and 30-day in-hospital mortality in patients with pancreatic cancer: A retrospective matched-pair cohort study in Japan.

統合失調症合併症が膵臓癌患者の予後に影響

対象DB：DPC

55. Increased Periprosthetic Joint Infection Rate Following Total Knee Arthroplasty in Rheumatoid Arthritis Patients: Insights From a Japanese Nationwide Medical Claims Database Study.

RA患者はTKA後に感染と認知障害が多発

対象DB：DPC

56. Early initiation of oral intake on length of hospital stay in postoperative patients admitted to the intensive care unit.

早期経口摂取で術後入院日数が短縮

対象DB：DPC

57. Demographic and Clinical Trends in Adult Tracheostomy: Analysis of a Japanese Inpatient Database.

気管切開は主に呼吸疾患、早期施行は少数

対象DB：DPC

58. Association between initial intravenous fluid volume and the composite outcome of hemodialysis dependence at discharge or in-hospital mortality in inpatients with rhabdomyolysis.

過剰輸液で死亡・透析率に差なし、透析依存は減

対象DB：DPC

59. Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database.

リチャレンジ後、ILD再発は18.9%に発生

対象DB：DPC

60. Outcomes and cost-effectiveness of intermediate care units for patients discharged from the intensive care unit: a nationwide retrospective observational study.

IMCU転棟で死亡率と再入室率が低下

対象DB：DPC

61. Surgery within Two Days of Admission Reduces Complications and Mortality of Patients with Trochanteric Femur Fractures: A Japanese DPC Study.

入院2日以内の手術で合併症と死亡率が低下

対象DB：DPC

62. Inpatient Burden of COVID-19 in Japan: A Retrospective Cohort Study.

COVID-19はインフルエンザより入院負担が高い

対象DB：MDV

63. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Initiation in Japanese Patients with Asthma Previously on Inhaled Corticosteroid/Long-Acting beta(2)-Agonist Therapy: A Retrospective Cohort Study.

FF/UMEC/VI追加で喘息増悪と薬剤使用が有意に減少

対象DB：MDV

64. Clinical characteristics of patients with difficult-to-treat ulcerative colitis: a nested case-control study using a Japanese claims database.

D2T UC患者は16.7％、コルチコステロイド高用量が関連

対象DB：MDV

65. The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan).

mCSPC初期治療にAPA+ADTが予後改善

対象DB：MDV

66. Use of gabapentinoid treatment and the risk of self-harm: population based self-controlled case series study.

自己傷害リスクは治療前後に上昇。継続中は安定

対象DB：CPRD

67. Treatment Persistence and Variations in Prescribing Oral, Injectable, and Inhaled Corticosteroids: A Population-Based Drug Utilisation Study.

経口・吸入CSの処方は一部患者に集中

対象DB：CPRD

68. Mother and Infant Research Electronic Data Analysis (MIREDA): A protocol for creating a common data model for federated analysis of UK birth cohorts and the life course.

英国の電子出生コホートを統合し研究基盤化

対象DB：CPRD

69. Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.

サクセンダとビクトーザは概ね適応通り使用

対象DB：CPRD

70. COVID-19 pandemic and risk factor measurement in individuals with cardio-renal-metabolic diseases: A retrospective study in the United Kingdom.

COVID-19で糖尿病等のリスク因子評価が減少

対象DB：CPRD

71. Estimating the clinical and healthcare burden of metabolic dysfunction-associated steatohepatitis in England: a retrospective cohort study using routinely collected healthcare data from 2011 to 2020.

MASH進行や併存症により医療費と利用量が増加

対象DB：CPRD

72. Defining phenotypes of disease severity for long-term cardiovascular, renal, metabolic, and mental health conditions in primary care electronic health records: A mixed-methods study using the nominal group technique.

EHRで実行可能な重症度指標を特定し有用性を確認

対象DB：CPRD

73. Maternal Anaemia and Congenital Heart Disease in Offspring: A Case-Control Study Using Linked Electronic Health Records in the United Kingdom.

妊娠初期の母体貧血は児の先天性心疾患リスクを増加

対象DB：CPRD

74. Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study.

COPD三剤療法は多くがガイドライン準拠

対象DB：THIN

75. Longitudinal comparative analysis of antidepressants and anti-anxiety medications in Alzheimer's and Parkinson's diseases: insights from French and British health records.

ADでは診断前後で抗うつ薬処方が増加

対象DB：THIN

76. Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.

リルザブルチニブはCSUに有効で忍容性も良好

対象DB：CVAR

77. Evaluating the Chinese versions of delirium assessment scales: a diagnostic systematic review.

中国語版せん妄評価尺度は高い妥当性と信頼性を示す

対象DB：DeSC

78. Mechanical Thrombectomy vs Catheter-Directed Thrombolysis for High-Risk Pulmonary Embolism: A Target Trial Emulation.

高リスク肺塞栓のMTとCDT治療効果は同等

対象DB：DeSC